KKR Acquires Majority Stake in Healthcare Royalty Management
PorAinvest
miércoles, 30 de julio de 2025, 2:22 pm ET1 min de lectura
KKR--
HCRx, founded in 2006 and headquartered in Stamford, Connecticut, has a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets. Since its inception, the firm has committed over $7 billion in capital and today manages approximately $3 billion in assets, with a portfolio spanning over 10 therapeutic areas and over 55 products [1].
Clarke Futch, HCRx's Chairman and CEO, will continue to lead the company and will maintain an ongoing substantial minority interest in HCRx. The HCRx team will collaborate closely with KKR's health care team to provide a range of financing solutions across the biopharma sector [1].
"This acquisition supports KKR’s ability to provide comprehensive solutions across the health care spectrum and meaningfully expands our life sciences capabilities to address market demand," said Ali Satvat, Partner, Co-Head of Health Care and Global Head of Health Care Strategic Growth at KKR [1].
TD Securities Inc. served as the exclusive financial advisor to HCRx in this transaction [1].
References:
[1] https://finance.yahoo.com/news/kkr-announces-strategic-acquisition-healthcare-130000704.html
[2] https://www.nasdaq.com/articles/kkr-co-acquires-majority-ownership-stake-hcrx
[3] https://www.businesswire.com/news/home/20250730161531/en/KKR-Announces-Strategic-Acquisition-of-HealthCare-Royalty-Partners-Expanding-the-Firms-Health-Care-Franchise-and-Enhancing-its-Life-Sciences-Strategy
RMCO--
KKR & Co. Inc. has acquired a majority stake in Healthcare Royalty Management, LLC, with Clarke Futch continuing to lead the company. TD Securities Inc. acted as financial advisor for HCRx. The acquisition was completed on July 30, 2025.
NEW YORK, July 2, 2025—KKR & Co. Inc., a leading global investment firm, has acquired a majority stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. The acquisition, completed on July 30, 2025, is part of KKR's strategy to expand its capabilities in biopharma royalty and credit investing, as well as its footprint in the life sciences ecosystem [1].HCRx, founded in 2006 and headquartered in Stamford, Connecticut, has a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets. Since its inception, the firm has committed over $7 billion in capital and today manages approximately $3 billion in assets, with a portfolio spanning over 10 therapeutic areas and over 55 products [1].
Clarke Futch, HCRx's Chairman and CEO, will continue to lead the company and will maintain an ongoing substantial minority interest in HCRx. The HCRx team will collaborate closely with KKR's health care team to provide a range of financing solutions across the biopharma sector [1].
"This acquisition supports KKR’s ability to provide comprehensive solutions across the health care spectrum and meaningfully expands our life sciences capabilities to address market demand," said Ali Satvat, Partner, Co-Head of Health Care and Global Head of Health Care Strategic Growth at KKR [1].
TD Securities Inc. served as the exclusive financial advisor to HCRx in this transaction [1].
References:
[1] https://finance.yahoo.com/news/kkr-announces-strategic-acquisition-healthcare-130000704.html
[2] https://www.nasdaq.com/articles/kkr-co-acquires-majority-ownership-stake-hcrx
[3] https://www.businesswire.com/news/home/20250730161531/en/KKR-Announces-Strategic-Acquisition-of-HealthCare-Royalty-Partners-Expanding-the-Firms-Health-Care-Franchise-and-Enhancing-its-Life-Sciences-Strategy

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios